Business context and reporting period
The filing is On Assignment, Inc.’s unaudited Form 10-Q for the quarter ended September 30, 2015; the supplied metadata names Everforth Inc., which does not match the registrant identified in the filing. On Assignment provides staffing and related services through its Apex and Oxford segments. Unless stated otherwise, financial amounts below are in millions of dollars.
During 2015, the company acquired Creative Circle, expanding Apex into digital and creative staffing, and LabResource, expanding Oxford’s European life sciences business. It also sold its Physician Segment in February 2015; that business is reported as discontinued operations.
Financial performance and position
| Metric | Third quarter 2015 | Nine months 2015 |
|---|---|---|
| Revenue | $572.1; up 29.3% year over year | $1,487.5; up 15.9% |
| Gross profit / margin | $191.4 / 33.5%, versus $144.8 / 32.7% | $485.8 / 32.7%, versus $414.9 / 32.3% |
| Operating income | $51.5, versus $38.7 | $109.2, versus $102.0 |
| Income from continuing operations | $24.9, versus $20.7 | $52.2, versus $54.0 |
| Net income / diluted EPS | $24.9 / $0.47, versus $22.0 / $0.41 | $78.3 / $1.48, versus $56.7 / $1.03 |
| Operating cash flow | Not presented separately for the quarter | $87.3, versus $68.0 |
Q3 revenue growth reflected acquisitions and organic expansion: excluding the acquired businesses, revenue grew 12.2% year over year. Q3 gross-margin improvement reflected direct-hire and conversion-fee mix and Creative Circle; Oxford margin declined with business mix. For the nine months, reported net income included a $25.7 million after-tax gain on the Physician Segment sale; continuing-operations income declined year over year.
At September 30, cash was $28.9 million and working capital was $250.0 million. Long-term debt was $784.8 million net of loan costs, representing $804.0 million face value; the company reported $96.3 million available on its revolver and a 3.21-to-1.00 funded-debt-to-EBITDA ratio. Capital expenditures were $18.2 million for the nine months. Operating cash flow was offset by acquisition spending and working-capital investment; investing cash outflow was $455.5 million, including $552.8 million of net acquisition payments, partly offset by $115.4 million of sale proceeds.
Material changes, outlook, and risks
- Creative Circle was acquired for approximately $570 million at closing, with up to $30 million of additional performance-based consideration; LabResource was acquired for $12.7 million. Acquisition-related goodwill and intangible assets increased substantially.
- A new $975 million credit facility was entered into in June to refinance prior debt and fund Creative Circle. The term loan’s reported weighted-average interest rate was 3.68%; debt is secured by substantially all company assets and is subject to leverage and other restrictive covenants. The company stated it was covenant-compliant.
- Management said working capital, revolver availability, and expected operating cash flows should fund obligations and capital needs for the next 12 months. The filing provides no specific revenue or earnings guidance.
- Potential contingent consideration was approximately $41 million through the end of 2015; its recorded fair value was $18.2 million. Purchase-price allocations remained provisional. Ordinary-course legal matters were not expected to have a material financial effect.
- Risks highlighted include demand for staffing services, hiring and retaining qualified staff and contract professionals, competition, integration of acquisitions, growth execution, litigation, and economic conditions. A 100-basis-point interest-rate change was estimated to alter annual interest expense by approximately $8 million on debt outstanding at quarter-end.
- Management reported effective disclosure controls and no material change in internal control over financial reporting during the nine-month period.
Important facts for investors to verify
- Confirm the issuer identity: the filing names On Assignment, Inc., while the request metadata names Everforth Inc.
- Assess organic growth separately from acquisitions and confirm the contribution of Creative Circle and LabResource to reported segment performance.
- Track continuing-operations earnings separately from net income, which benefited from the Physician Segment sale gain.
- Monitor debt, leverage-covenant headroom, interest-rate exposure, and the remaining revolver capacity.
- Review final acquisition purchase-price allocations and the performance conditions and payment amounts for contingent consideration.
- Evaluate whether working-capital needs, especially receivables and payroll obligations, remain manageable as revenue grows.